Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled, Dose-Response Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy

NCT03755934 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03755934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03755934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled, Dose-Response Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
November 19, 2018
Completion date
June 29, 2023
Enrollment
112 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

painful diabetic neuropathy